Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00063583
Status:
COMPLETED
Last Update Posted:
2009-11-04
First Post:
2003-06-30
Brief Title:
Pirfenidone A New Drug to Treat Kidney Disease in Patients With Diabetes
Sponsor:
Sharma Kumar MD
Organization:
Sharma Kumar MD
Study Overview
Official Title:
Pirfenidone A Novel Anti-Scarring Therapy for Diabetic Nephropathy
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a new investigational drug pirfenidone will be an effective therapy for diabetic patients with kidney dysfunction Our hypothesis is that administration of pirfenidone to type 1 and type 2 diabetic patients with advanced kidney disease will lead to preservation of kidney function
Detailed Description:
Diabetic kidney disease is the leading cause of new cases of kidney failure in the United States In the kidneys of diabetic patients there is accumulation of protein that leads to the formation of scar tissue and poor kidney function Because of this many patients eventually require dialysis or kidney transplantation A new investigational drug pirfenidone has been shown to be beneficial in a number of diseases in which scar formation leads to disease progression It is our goal to examine whether pirfenidone is effective at stabilizing or reducing progressive diabetic kidney dysfunction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DK063017 | NIH | None | httpsreporternihgovquickSearchR01DK063017 |